Prevest Denpro Ltd Q1 FY2024 Concall Summary

Key Takeaways

• Export drag, domestic pull: Revenue grew ~8-9% YoY to INR14 crores as 17% domestic growth offset export weakness from global recession and FX crises.
• Profitability held firm: PAT rose 11% YoY to INR4.08 crores and EBITDA margin stayed at 40%, aided by cost management and a value-added product mix.
• New product pipeline is now tangible: A new oral care and disinfectant line awaits only regulatory clearance, and an in-house 3D dental resin is positioned as a multi-year adoption story.
• The 30% full-year target stands, but Q1 left a hole: Management reiterated the over-30% FY24 growth target from the prior call, which per an analyst's math now requires ~INR17 crores per quarter for the rest of the year.
• What to watch next quarter: Whether regulatory approvals unlock the new facility, whether export markets stabilize enough to close the gap to the 30% target, and any decision on the marketing director's commission structure.

Domestic Engine

• 17% growth carried the quarter: Domestic sales compensated for flat exports, with the company adding 7 new dealers and estimating the domestic market itself grew 8-10% over last year.
• Market share inching up: In a domestic market dominated by MNCs, Prevest's share has moved from roughly 2% to approximately 2.5-3%, though management did not state a target share when asked.
• New distribution layer being built: A wholly owned subsidiary, Denvisio Biomed Limited, has been incorporated and entrusted with sales and marketing responsibility for the entire product line, with a professional team now being assembled.
• Commission question unresolved: An analyst challenged the marketing director's 2% commission on domestic sales above INR20 crores as detrimental to shareholders and suggested ESOPs instead. Management acknowledged the request and said it would review the structure if ESOPs are introduced, but gave no commitment to change.

Export Headwinds

• Recession and FX crises hit exports: The export business did not deliver anticipated growth, with management citing ongoing global recession and foreign exchange crises in multiple countries as the binding constraints.
• Mitigation is a search, not a plan: The company is trying other international opportunities to cover the business loss in affected countries, but no specific new markets or contracts were named.
• The US market looms large: Management noted the global dental materials market is \$20-25 billion, with the US alone at \$8.5 billion, implying a large addressable opportunity that current export weakness is not capturing.

Atul Modi: "The only risk which can challenge is the export foreign exchange situation and the recession in the international market. Other than that, we don't foresee any risk at the moment."

New Products & Capacity

• Oral care and disinfectant line ready, pending clearance: The new plant is fully commissioned with test runs completed, and documents have been submitted to CDSCO and the state FDA, with an initial inspection due the day after the call. Commercial production starts once approvals arrive.
• 3D dental resin developed in-house: The company has developed a dental 3D resin meeting international quality standards, calling it a game-changing opportunity, and expects 3D printing to become a normal fixture in every dental clinic within four to five years.
• Modest near-term revenue from 3D printing: Management expects turnover of INR2-2.5 crores from 3D printing resins in the next two years, a small contributor relative to the overall growth target.
• Import substitution yielding savings: R&D has achieved complete raw material substitution for around four products, including high-value substances like hydroxyapatite, with expected annual cost savings of about INR1 crore.
• Capacity headroom for five years: Current utilization is 40% on a single-shift basis, and the INR35 crore investment in R&D and the new facility means no further capex is needed for the next five years.

Sai Kalyan: "The 3D printing, okay, it's a very new growing market in India. Probably, I would say in the next not two or three years, in the next four to five years, it will be a normal thing. In every dental clinic, they would have 3D resin and a 3D printer as a standalone unit like 10 years ago."

Margins & Investment

• 40% EBITDA margin sustained: The margin held at approximately 40% through prudent cost management and enhanced productivity, and management intends to maintain this level going forward.
• Investment phase funded without dividend from promoters: Promoters forewent their final dividend for the fiscal year to support heavy R&D and new market segment investment, while the board still approved a 10% final dividend for other shareholders.
• Marketing spend budgeted but not yet deployed: A budget has been allocated for marketing new products, and management believes existing profit margins can absorb the new product line without straining funds.
• Geographic margin split unavailable: When asked for the margin split between domestic and export business, management said bifurcated figures were not available at present but could be provided later.

Guidance & Commitments

Key Metrics